A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum() metallacycle for efficient cancer imaging and therapy

• Published in: Chemical science (Cambridge) 2019-08, Vol.1 (29), p.723-728
• Main Authors: Ding, Feng, Chen, Zhao, Kim, Won Young, Sharma, Amit, Li, Chonglu, Ouyang, Qingying, Zhu, Hua, Yang, Guangfu, Sun, Yao, Kim, Jong Seung
• Format: Article
• Language: English
• Subjects: Anticancer properties; Cancer therapies; Diagnostic systems; Drug delivery systems; In vivo methods and tests; Medical imaging; Monitoring; Organometallic compounds; Poloxamers; Real time; Therapy; Xenotransplantation
• ISSN: 2041-6520; 2041-6539
• DOI: 10.1039/c9sc02466b

The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum( ii ) metallacycles P1 and an organic NIR-II molecular dye, SY1030 , into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest that PSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt( ii )-based anticancer drug, cisplatin. The engineered nano-cocktail PSY offers a simple strategy for delivering the organoplatinum( ii ) macrocycle P1 and NIR-II fluorophore SY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment. A novel NIR-II theranostic nanoprobe, PSY (∼110 nm), was concisely developed, which demonstrated excellent photostability, high tumor uptake, superior S/N ratios and more efficient cancer treatment with minimal side effects than cisplatin.